BMJ guideline gives a weak recommendation to try non-inhaled medical cannabis for chronic pain
An international clinical guideline issued a weak recommendation to offer non-inhaled medical cannabis for chronic cancer and non-cancer pain when standard treatments are insufficient, based on small improvements in pain, function, and sleep.
Quick Facts
What This Study Found
The guideline panel issued a weak recommendation to offer a trial of non-inhaled medical cannabis or cannabinoids as add-on therapy for chronic pain when standard care is insufficient. This reflects small to very small improvements in pain intensity, physical functioning, and sleep quality, balanced against a small to modest risk of mostly self-limited harms.
Key Numbers
Weak recommendation; small to very small improvements in pain, function, and sleep; small to modest risk of mostly self-limited harms; non-inhaled forms recommended
How They Did This
International guideline developed using GRADE methodology with patient, clinician, and methodologist input, informed by four linked systematic reviews on benefits, harms, and patient values regarding medical cannabis for chronic pain.
Why This Research Matters
This is one of the most rigorous clinical guidelines on medical cannabis for pain, providing a framework for shared decision-making between patients and clinicians based on the best available evidence.
The Bigger Picture
This guideline lands in the middle of a contentious debate, acknowledging both the potential benefits and the limitations of cannabis for chronic pain while emphasizing individual patient preferences and shared decision-making.
What This Study Doesn't Tell Us
Weak recommendation reflects close balance between benefits and harms. Evidence quality is variable. Further research may change the recommendation. Does not address inhaled cannabis.
Questions This Raises
- ?Should inhaled forms be included in future guideline updates?
- ?Which specific cannabinoid formulations are most effective for different pain types?
- ?How should clinicians implement shared decision-making for medical cannabis?
Trust & Context
- Key Stat:
- Weak recommendation to offer non-inhaled medical cannabis when standard care is insufficient
- Evidence Grade:
- GRADE-based international clinical practice guideline informed by four systematic reviews
- Study Age:
- Published in 2021. This guideline may be updated as new evidence emerges.
- Original Title:
- Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.
- Published In:
- BMJ (Clinical research ed.), 374, n2040 (2021)
- Authors:
- Busse, Jason W(7), Vankrunkelsven, Patrick, Zeng, Linan, Heen, Anja Fog, Merglen, Arnaud, Campbell, Fiona, Granan, Lars-Petter, Aertgeerts, Bert, Buchbinder, Rachelle, Coen, Matteo, Juurlink, David, Samer, Caroline, Siemieniuk, Reed A C, Kumar, Nimisha, Cooper, Lynn, Brown, John, Lytvyn, Lyubov, Zeraatkar, Dena, Wang, Li, Guyatt, Gordon H, Vandvik, Per O, Agoritsas, Thomas
- Database ID:
- RTHC-03037
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Does medical cannabis work for chronic pain?
This BMJ guideline found small to very small improvements in pain, function, and sleep from medical cannabis. The benefits are real but modest, and the panel issued a weak recommendation to try it when standard treatments are insufficient.
What form of medical cannabis is recommended for pain?
The guideline specifically recommends non-inhaled forms (such as oils, capsules, or sprays) rather than smoked or vaporized cannabis, as add-on therapy to standard pain management.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03037APA
Busse, Jason W; Vankrunkelsven, Patrick; Zeng, Linan; Heen, Anja Fog; Merglen, Arnaud; Campbell, Fiona; Granan, Lars-Petter; Aertgeerts, Bert; Buchbinder, Rachelle; Coen, Matteo; Juurlink, David; Samer, Caroline; Siemieniuk, Reed A C; Kumar, Nimisha; Cooper, Lynn; Brown, John; Lytvyn, Lyubov; Zeraatkar, Dena; Wang, Li; Guyatt, Gordon H; Vandvik, Per O; Agoritsas, Thomas. (2021). Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.. BMJ (Clinical research ed.), 374, n2040. https://doi.org/10.1136/bmj.n2040
MLA
Busse, Jason W, et al. "Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.." BMJ (Clinical research ed.), 2021. https://doi.org/10.1136/bmj.n2040
RethinkTHC
RethinkTHC Research Database. "Medical cannabis or cannabinoids for chronic pain: a clinica..." RTHC-03037. Retrieved from https://rethinkthc.com/research/busse-2021-medical-cannabis-or-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.